Comparative Pharmacology
Head-to-head clinical analysis: BROMFENAC SODIUM versus ILEVRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMFENAC SODIUM versus ILEVRO.
BROMFENAC SODIUM vs ILEVRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing prostaglandin synthesis, leading to decreased inflammation, pain, and fever. Specifically, bromfenac is a potent inhibitor of COX-2.
Nepafenac is a prodrug that is metabolized to amfenac, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis.
One drop (0.1 mL) of 0.09% ophthalmic solution (bromfenac 0.9 mg/mL) instilled into the affected eye(s) twice daily beginning 24 hours before cataract surgery and continuing on the day of surgery and for 14 days postoperatively.
1 drop of the 0.3% ophthalmic solution administered to the affected eye(s) four times daily.
None Documented
None Documented
Terminal elimination half-life: 1.5-2.5 hours (prolonged in renal impairment; clinical context: short half-life supports twice-daily dosing in ophthalmic use)
Terminal elimination half-life of amfenac is approximately 0.7 hours in plasma, but due to prolonged residence in ocular tissues, the clinical effect lasts up to 24 hours with once-daily dosing.
Renal: ~80% (primarily as unchanged drug and glucuronide conjugate); Biliary/Fecal: ~20%
Nepafenac is extensively metabolized, and its active metabolite amfenac is primarily excreted renally (approximately 80% as metabolites, including amfenac glucuronide, and 20% as unchanged drug in urine). Biliary/fecal excretion accounts for less than 10%.
Category C
Category C
Ophthalmic NSAID
Ophthalmic NSAID